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Abstract 
Binding of proteins with SH2 domains to tyrosine-phosphorylated signaling proteins is a key 
mechanism for transmission of biological signals within the cell. Characterization of 
dysregulated proteins in cell signaling pathways is important for the development of therapeutic 
approaches. The AKT pathway is a frequently upregulated pathway in most cancer cells and 
the SH2-containing inositol 5-phosphatase SHIP1 is a negative regulator of the AKT pathway. 
In this study we investigated different mutations of the conserved FLVR motif of the SH2 
domain and putative phosphorylation sites of SHIP1 which are located in close proximity to its 
FLVR motif. We demonstrate that patient-derived SHIP1-FLVR motif mutations e.g. F28L, 
and L29F possess reduced protein expression and increased phospho-AKT-S473 levels in 
comparison to SHIP1 wildtype. The estimated half-life of SHIP1-F28L protein was reduced 
from 23.2 h to 0.89 h in TF-1 cells and from 4.7 h to 0.6 h in Jurkat cells. These data indicate 
that the phenylalanine residue at position 28 of SHIP1 is important for its stability. Replacement 
of F28 with other aromatic residues like tyrosine and tryptophan preserves protein stability 
while replacement with non-aromatic amino acids like leucine, isoleucine, valine or alanine 
severely affects the stability of SHIP1. In consequence, a SHIP1-mutant with an aromatic amino 
acid at position 28 i.e. F28W can rescue the inhibitory function of wild type SHIP1, whereas 
SHIP1-mutants with non-aromatic amino acids i.e F28V do not inhibit cell growth anymore. A 
detailed structural analysis revealed that F28 forms hydrophobic surface contacts in particular 
with W5, I83, L97 and P100 which can be maintained by tyrosine and tryptophan residues, but 
not by non-aromatic residues at position 28. In line with this model of mutation-induced 
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instability of SHIP1-F28L, treatment of cells with proteasomal inhibitor MG132 was able to 
rescue expression of SHIP1-F28L. In addition, mutation of putative phosphorylation sites S27 
and S33 adjacent to the FLVR motif of SHIP1 have an influence on its protein stability. These 
results further support a functional role of SHIP1 as tumor suppressor protein and indicate a 
regulation of protein expression of SH2 domain containing proteins via the FLVR motif. 
Keywords: SHIP1, SH2 domain, FLVR motif, instability 
 
Introduction 
Dysregulated proteins in cell signaling pathways represent an important starting point for the 
establishment of therapeutic approaches. The comprehensive characterization of these signaling 
networks and identification of relevant proteins acting as regulators to inhibit the growth and 
survival of the tumor cell are therefore of utmost importance to the understanding of cancer. 
The PI3K/AKT/mTOR signaling pathway plays a key role in cancer therapy because of its 
frequent overactivation in most tumors (Kandoth et al., 2013). The inositol phosphatase SHIP1 
(src homology 2 domain-containing inositol phosphatase 1) serves as a negative regulator of 
the PI3K/AKT signaling pathway. In recent years SHIP1 has also been identified as an 
important tumor suppressor (Horn et al., 2004; Pedersen et al., 2009; Miletic et al., 2010; Brauer 
et al., 2012; Ehm et al., 2015, Täger et al., 2017). 
SHIP1 possesses important functions as a negative regulator of signal transduction in 
hematopoietic cells. The regulatory function of SHIP1 is mediated by its inositol 5-phosphatase 
activity, catalyzing dephosphorylation of phosphoinositides (PI) and inositol phosphates (IP) at 
the D5 position of the inositol ring. Regulation of phosphoinositide- and inositol phosphate-
mediated cellular processes by SHIP1 (especially conversion of PtdIns (3,4,5)P3 to PI(3,4)P2 
and Ins(1,3,4,5)P4 to Ins(1,3,4)P3) has been extensively studied (Damen et al., 1996; Drayer et 
al., 1996; Ware et al., 1996; Odai et al., 1997). 
 
Several experimental data strongly suggest that reduced expression and/or reduced activity of 
SHIP1 plays an important role in leukemogenesis. In T cell acute lymphoblastic leukemia (T-
ALL) expression of full length SHIP1 is frequently down regulated (Lo et al, 2009). 
Simultaneous deletion of SHIP1 and PTEN in a mouse model led to development of lethal B-
cell lymphomas (Miletic et al., 2010). In contrast, deletion of PTEN or SHIP1 alone did not 
result in malignancy in this animal model (Miletic et al., 2010). PTEN and SHIP1 are apparently 
cooperative in suppressing B-cell lymphoma. In contrast, lentiviral mediated overexpression of 
SHIP1 alone in a xenograft transplantation model of acute myeloid leukemia resulted in 
significantly prolonged survival of the mice compared to control cohort (Täger et al., 2017). 
Furthermore, expression of SHIP1 is down regulated by BCR–ABL and SHIP1 is barely 
detectable in BCR/ABL-positive chronic myeloid leukemia (Sattler et al., 1999). In addition, 
Friend murine leukemia virus leads to activation of Fli-1 and, in turn, suppresses the expression 
of SHIP1. This is associated with an accelerated development of erythroleukemia in mice 
(Lakhanpal et al., 2010).  
 
The Src homology 2 (SH2) domain is a sequence-specific phosphotyrosine-binding module 
present in many signaling proteins. Therefore, recognition and binding of proteins with SH2 
domains to tyrosine-phosphorylated signaling proteins is a key mechanism for the transmission 
of many important biological signals within the cell. The SH2 domain is responsible for cellular 
localization, substrate recruitment and, in some cases, regulates kinase activity 
(Filippakopoulos et al., 2009). As such the SH2 domain plays a role in stabilizing the inactive 
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state of Src-kinase family members, but it also stabilizes the active kinase conformation of Fes 
(Liu et al., 1993; Filippakopoulos et al., 2008).  
Furthermore, mutations in the SH2 domain have been shown to destabilize some signaling 
proteins and cause various diseases. The kinases Fer (W460), ZAP-70 (P80Q), Jak3 (E481G), 
ITK (R335W) and BTK (different mutations) show mutations that affect their SH2 domains 
(Richardson et al., 2009; Matsuda et al., 1999; Candotti et al., 1997; Huck et al., 2009; 
Lappalainen et al., 2008). These mutations are for the most part not involved in phosphotyrosine 
binding and lead to instability, reduced half-life, and in consequence, increased protein 
degradation (Filippakopoulos et al., 2009). As a result, kinase activity is impaired in mutants 
that destabilize the SH2 domain. 
The SH2 domain of SHIP1 is important in the context of recruitment of SHIP1 to the cell 
membrane, where it binds, for example, to the immunoreceptor tyrosine-based inhibitory motif 
(ITIM) of the inhibitory receptor Fc gamma receptor IIB (FcγRIIB) and serves as negative 
regulator of the AKT pathway (Pauls and Marshall, 2017). Mutations of the INPP5D gene 
(SHIP1) in hematopoietic and lymphoid cells are relatively rare (10 mutations out of 4226 
primary tissue samples tested, corresponding to 0.24% of  all tested cases) (Forbes et al., 2008). 
In patients with acute myeloid leukemia (AML), some mutations in the INPP5D gene encoding 
SHIP1 have been described, thereby implicating mutated SHIP1 in the pathogenesis of AML 
(Luo et al., 2004; Zhang et al., 2006; Gilby et al., 2007; Brauer et al., 2012). Interestingly, 
mutations of the INPP5D gene have also been described for large intestine carcinoma (89 out 
of 2320; 3.84%), melanoma (76 out of 1280; 5.94%) and different other carcinomas in higher 
numbers (Forbes et al., 2008). 
However, the molecular mechanisms of how SHIP1 mutations may impair its function as a 
tumor suppressor must be further illuminated in detail. Knowledge is particulary limited about 
mutations of SHIP1 that can lead to the instability of the protein. In this study we analyze 
mutations and putative phosphorylation sites of SHIP1, which affect its FLVR motif or are 
located in close proximity to its FLVR motif within the SH2 domain. We demonstrate that 
SHIP1 FLVR motif mutations derived from patients possess reduced protein expression and 
shorter half-life. In addition, we have presumably identified FLVR motif flanking 
phosphorylation sites that are involved in regulation of protein expression. 
 
Material and Methods 
Construction of plasmids 
LeGO-iG2-Puro+ SHIP1 vector was generated as previously described (Ehm et al., 2015). The 
vector was generated by using modified QuikChange site-directed mutagenesis (Wang and 
Malcolm, 1999). The LeGO-iG2-Puro+ SHIP1 vector was used as template. The following 
primer pairs were used: 
 
K24R 
K24R-FP: 5´- CTTTCCAGGACAGGCAGGGACGGGAGCTTCCTC-3´                  
K24R-RP: 5´- GAGGAAGCTCCCGTCCCTGCCTGTCCTGGAAAG-3´   
 
S27A 
S27A-FP: 5´- ACAGGCAAGGACGGGGCCTTCCTCGTGCGTGCC-3´                  





S27D-FP: 5´- ACAGGCAAGGACGGGGACTTCCTCGTGCGTGCC-3´                  
S27D-RP: 5´- GGCACGCACGAGGAAGTCCCCGTCCTTGCCTGT-3´                  
 
F28I 
F28i-FP: 5´- GGCAAGGACGGGAGCATCCTCGTGCGTGCCAGC-3´                  
F28i-RP: 5´- GCTGGCACGCACGAGGATGCTCCCGTCCTTGCC-3´                  
 
F28V 
F28V-FP: 5´- GGCAAGGACGGGAGCGTCCTCGTGCGTGCCAGC-3´                  




F28A-FP: 5´- GGCAAGGACGGGAGCGCCCTCGTGCGTGCCAGC-3´                  
F28A-RP: 5´- GCTGGCACGCACGAGGGCGCTCCCGTCCTTGCC-3´                  
 
F28Y 
F28Y-FP: 5´- GGCAAGGACGGGAGCTACCTCGTGCGTGCCAGC-3´                  
F28Y-RP: 5´- GCTGGCACGCACGAGGTAGCTCCCGTCCTTGCC-3´                  
 
F28W 
F28W-FP: 5´- GGCAAGGACGGGAGCTGGCTCGTGCGTGCCAGC-3´                  
F28W-RP: 5´- GCTGGCACGCACGAGCCAGCTCCCGTCCTTGCC-3´                  
 
L29F 
L29F-FP: 5´- AAGGACGGGAGCTTCTTCGTGCGTGCCAGCGAG-3´                  
L29F-RP: 5´- CTCGCTGGCACGCACGAAGAAGCTCCCGTCCTT-3´                  
 
R31Q 
R31Q-FP: 5´- GGGAGCTTCCTCGTGCAGGCCAGCGAGTCCATC-3´                  
R31Q-RP: 5´- GATGGACTCGCTGGCCTGCACGAGGAAGCTCCC-3´                  
 
Delta FLVR 
Delta FLVR-FP: 5´- GGCAAGGACGGGAGCGCCAGCGAGTCCATC-3´                  
Delta FLVR-RP: 5´- GATGGACTCGCTGGCGCTCCCGTCCTTGCC-3´                  
 
S33A 
S33A-FP: 5´- TTCCTCGTGCGTGCCGCCGAGTCCATCTCCCGG-3´                  
S33A-RP: 5´- CCGGGAGATGGACTCGGCGGCACGCACGAGGAA-3´                  
 
S33D 
S33D-FP: 5´- TTCCTCGTGCGTGCCGACGAGTCCATCTCCCGG-3´                  
S33D-RP: 5´- CCGGGAGATGGACTCGTCGGCACGCACGAGGAA-3´                  
               
S35A 
S35A-FP: 5´- GTGCGTGCCAGCGAGGCCATCTCCCGGGCATAC-3´                  
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S35A-RP: 5´- GTATGCCCGGGAGATGGCCTCGCTGGCACGCAC-3´                  
 
S35D 
S35D-FP: 5´- GTGCGTGCCAGCGAGGACATCTCCCGGGCATAC-3´                  
S35D-RP: 5´- GTATGCCCGGGAGATGTCCTCGCTGGCACGCAC-3´                  
 
Y40A 
Y40A-FP: 5´- TCCATCTCCCGGGCAGCCGCGCTCTGCGTGCTG-3´                  
Y40A-RP: 5´- CAGCACGCAGAGCGCGGCTGCCCGGGAGATGGA-3´                  
 
Y46A 
Y46A-FP:  5´- GCGCTCTGCGTGCTGGCTCGGAATTGCGTTTAC-3´                  
Y46A-RP: 5´- GTAAACGCAATTCCGAGCCAGCACGCAGAGCGC-3´                  
 
 
Lentiviral knockdown  
Generation of pseudotyped lentiviruses and transduction were performed as previously 
described (Metzner et al., 2009). 293-T cells were co-transfected with the plasmids Gag-Pol 
(HIV-1 GAG/POL), Rev (HIV1gp6), VSV-G env and target vector DNA.  
Target cells were seeded at a density of 5×105 cells per 6-well. Two ml of fresh culture medium 
and 2 ml of virus supernatant were added. Transduced cells were selected by addition of 
puromycin (Sigma-Aldrich) to culture medium for at least 1 week before experiments were 
carried out. 
 
Western blot analysis and determination of protein half-life 
To avoid rapid degradation of cellular proteins due to protease activity, cells were lysed directly 
in cold 150mM NaCl supplemented with 10% (w/v) trichloroacetic acid (TCA) for 30 minutes. 
After centrifugation, the supernatant was discarded and the pellet was solved in an appropriate 
volume of 1x loading buffer. The cell pellet was then sonicated at 4°C. Insoluble particles were 
separated by centrifugation at 4°C and 13,000 x g for 5 min. The supernatant was transferred 
to fresh tubes. The protein lysates were stored at -80°C. 
 Proteins were analyzed by SDS–polyacrylamide gel electrophoresis and transferred to 
nitrocellulose membrane. As a loading control, Ponceau S staining of the membrane was 
performed. Subsequently, the membrane was hybridized with either rat anti-HA High Affinity 
antibody (Roche), mouse anti-SHIP1 antibody (P1C1) or mouse anti-HSC70 antibody (B-6) 
(both Santa Cruz). Further antibodies used were anti-mouse IgG HRP-conjugated, anti-rabbit 
IgG HRP-conjugated (both Cell Signaling) and goat anti-rat IgG HRP (Santa Cruz).  
Protein half-life was determined by treatment with cycloheximide (Sigma-Aldrich) for 0 – 24 
hours before lysis and Western blotting. Subsequently, protein expression was quantified using 
LAS-3000 Imager from Fuji (Raytest). Ponceau S staining was used to normalize the abundance 
of SHIP1 to the total amount of protein in each lane. Intensity of the Western blot band observed 
at time point 0h (untreated) was set to 100%. Protein half-life was calculated by the use of 
GraphPad Prism program. Exponential decay and asymptotic approach to zero were assumed. 
 
RNA isolation, cDNA synthesis and real-time quantitative PCR (qPCR) 
Total RNA was isolated with the Direct-Zol RNA MiniPrep Kit (ZYMO Research) following 
the manufacturer's instruction. First strand cDNA was synthesized with the Promega M-MLV 
Reverse Transcriptase (Promega) following the manufacturer's instruction. 
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Sense and antisense oligonucleotide primers for amplification of mRNAs of human SHIP1 and 
the housekeeping genes GAPDH were designed as followed:  
 
SHIP1 FP: 5´- CCTATGACGTGCCCGACTATGC-3´;  
SHIP1 RP: 5´-AGCGGCACAGGGTATTGCAGATGGGTC-3´;  
GAPDH-FP: 5´- GAGTCAACGGATTTGGTCGT-3´;                      
GAPDH-RP: 5´- TTGATTTTGGAGGGATCTCG-3´      
                              
Oligonucleotide primers were obtained from MWG. QPCR was performed on LightCycler 
(Roche). 
 
Determination of cell growth by live cell imaging 
For determination of cell growth, 3 × 104 cells were seeded in 200 μl medium per 96 well and 
allowed to adhere and grow for the indicated time. Cells were incubated during this time at 
37 °C in a humidified atmosphere. The live-cell-imaging system IncucyteZoom (Sartorius) 
enables automated quantification of cell behavior, especially cell growth, over time by 
automatically collecting and analyzing images at any time. 
 
 
Cell viability assay 
For the Alamar Blue cell viability assay 3 × 104 cells were seeded in 100 μl medium per 96 
well and allowed to adhere and grow for the indicated time. Prior to measurement 100 μl 
medium containing 5 ng/ml resazurin (Sigma-Aldrich) was added to each well. Cells were 
incubated for 60–240 min at 37 °C in a humidified atmosphere. Fluorescence based absorption 




The structure of SHIP1-wt and the F28L mutant were modelled based on the NMR structures 
deposited under PDB entry 2YSX. The 20 deposited protein conformations show a moderate 
degree of flexibility around residue 28, for which reason Figure 6 only shows on (i.e. the first) 
conformer. The mutation was introduced with the Mutate Residue function in Maestro 
[Maestro, Schrödinger version 2018-3, New York, NY, 2018]. The protein structures were 
prepared using the Maestro Protein Preparation Wizard (structure preprocessing with default 
settings; restrained minimization with the OPLS3e force field and default settings). 
 
Results 
Patient derived FLVR-motif mutation F28L leads to reduced SHIP1 protein expression 
SHIP1 mutations provide an interesting basis for the functional understanding and analysis of 
structural elements, such as domains and motifs of this protein. Interestingly, analysis of 
Cosmic database (https://cancer.sanger.ac.uk/cosmic) revealed a number of SHIP1-mutations 
derived from leukemia patients and patients with other tumors that either, affect its FLVR motif 
(residues 28-31) or are located in close proximity to its FLVR motif. These mutations include 
F28L (AML), L29F (malignant melanoma), L29L (lung carcinoma), R31H (mesothelioma), 
S33T (ovarian carcinoma), S33S (breast carcinoma), S37P (biliary cancer), R38Q (lung 
carcinoma), A41T (colon carcinoma), A41V (prostate carcinoma) and R47W (malignant 
melanoma). In addition, analysis of the PhosphoSite database (Hornbeck et al., 2004) revealed 
that a number of putative phosphorylation sites (P) and one ubiquitinylation site (Ub) are 
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located in close proximity to the FLVR motif of SHIP1. These sites include amino acids K24 
(Ub), S27 (P), S35 (P), Y40 (P) and Y46 (P) (Figure 1A). 
A reduced binding to tyrosine phosphorylated proteins has already been described for the 
SHIP1-F28L mutation (Brauer et al., 2012). First, TF-1 cells were transduced with control 
vector, SHIP1 wt, SHIP1-F28L and a mutant with reduced SHIP1 phosphatase activity 
(Y643H). The cells were then selected with puromycin. Subsequently, protein lysates were 
prepared by TCA precipitation and analyzed by Western Blot. 
The results in Figure 1B confirm that F28L mutant, unlike SHIP1 wild type and SHIP1-Y643H 
mutant, shows lower SHIP1 expression. Only after a very long exposure SHIP1-F28L protein 
was detected. 
In order to investigate whether the reduction of SHIP1 expression takes place at the 
transcriptional or translational level, mRNA level of SHIP1 was determined by RT-qPCR. The 
results of this experiment are shown in Figure 1C. Interestingly, SHIP1 mRNA level of SHIP1-
wt, SHIP1-F28L and SHIP1-Y643H are comparable. Thus, the reduction of SHIP1 expression 
seems to occur at the protein level. 
The next step was to investigate whether the SHIP1-F28L mutant is actively degraded. For this 
purpose, cells expressing SHIP1-F28L were inhibited with the Src kinase inhibitor PP2 or with 
an inhibitor for proteasomal degradation, MG-132. The results in Figure 1D show that 
degradation of SHIP1-F28L mutant can be reduced by treatment with PP2 or MG-132 
compared to DMSO-treated cells. 
 
An aromatic amino acid at position 28 of SHIP1 is important for its protein stability 
The next step was to investigate the influence of aromatic amino acids on the stability of the 
SHIP1 protein at position 28. For mimicking F28, the structurally similar amino acids tyrosine 
and tryptophan were selected. In addition, to simulate L28, SHIP1 mutants with the amino acids 
alanine, valine and isoleucine were generated. Also, a mutant was generated which lacks the 
complete FLVR motif (ΔFLVR) of SHIP1. Together, control vector, SHIP1-wt and SHIP1-
mutant DNA were transduced into H1299 cells. Cells were selected with puromycin. 
Subsequently, protein lysates were prepared by TCA precipitation and analyzed by Western 
Blot. 
SHIP1-F28Y (158%±15.5%) and F28W (125.4%±8.9%) had a strong expression of SHIP1 
even stronger than that of the SHIP1-wt (Figure 2A). In contrast, SHIP1 mutations F28L 
(1%±0.5%), F28I (7.2%±2.8%), F28V (8.5%±3.5%), F28A (7.4%±1.0%), and ΔFLVR 
(16.4%±7.0%) showed a markedly reduced SHIP1 expression in comparison to SHIP1-wt. 
In addition, cells expressing SHIP1-wt (20.8%±6.8%), F28Y (24.8%±10.9%) and F28W 
(14.9%±8.9%) showed a marked reduction of AKT phosphorylation (S473) compared to 
control vector-expressing cells. SHIP1-F28L mutant led to a reduction of AKT phosphorylation 
(S473) compared to vector control (40.4%±7.0%). In contrast, SHIP1-mutants F28I 
(88.1%±24.5%), F28V (140.6%±22.9%), F28A (106.6%±23.3%) and ΔFLVR 
(116.9%±12.6%) showed marginal or no changes of phosphorylation of AKT-S473 compared 
to vector control. 
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In order to check whether the SHIP1 mRNA quantity of all mutants is comparable, SHIP1 
mRNA was determined by RT-qPCR. The results of this study are shown in Figure 2C. The 
SHIP1 mRNA amounts of SHIP1-wt and the examined SHIP1 mutants were comparable. So in 
consequence, an aromatic amino acid at position 28 of SHIP1 is important for its protein 
stability 
 
Influence of FLVR motif flanking modification sites on protein stability of SHIP1 
The next step was to investigate the effect of further SHIP1 mutations within the FLVR motif 
(L29F and R31Q). In addition, the effects of putative phosphorylation sites S27, S33, S35, Y40 
and Y46 were investigated.  
For this purpose, pseudo-phosphorylation (S→D) and pseudo-dephosphorylation mutants 
(S→A) were prepared. Furthermore, the putative ubiquitinylation site K24 was examined more 
closely. Here, a mutant was created that impeded ubiquitinylation at position 24 (K→R). 
Together, control vector, SHIP1-wt and SHIP1-mutants were transduced into H1299 cells. 
Cells were selected with puromycin. Subsequently, protein lysates were prepared by TCA 
precipitation and analyzed by Western Blot.  
The results in Figure 3A and B show that SHIP1 mutants K24R (121%±10.5%), S27A 
(143%±16.5%), and S33D (190.5%±49.4%) had enhanced SHIP1 expression compared to 
SHIP1-wt. The mutants S35A (78.7%±8.4%) and S35D (87.2%±3.8%) showed a slightly lower 
SHIP1 expression compared to SHIP1 wt. In contrast, SHIP1 mutants S27D (7.1%±2.9%), 
F28L (1.4%±0.4%), L29F (5.2%±2.4%), R31Q (5%±3.1%), S33A (28.2%±6.3%), Y40A 
(28.5%±6.9%) and Y46A (23.1%±1.6%) showed a marked reduced expression compared to 
SHIP1-wt. 
K24R mutant showed the strongest reduction in phosphorylation of AKT-S473 (5.1%±3.5%) 
compared to vector control. In comparison to vector control, wild-type (18.6%±9.3%), S27A 
(22.2%±14.5%), S27D (35.8%±6.8%), F28L (40.4%±11.6%), L29F (59.8%±21.2%), R31Q 
(73%±5.9%), S33A (36.7%±20.2%), S33D (23%±18.2%), S35A (47.8%±13.3%), S35D 
(52.6%±14.0%), Y40A (71.1%±20.5%), and Y46A mutant (58.1%±36.3%) reduce the 
phosphorylation of AKT (S473). Only S27A (22.2%±14.5%) and S33D (23.0%±18.2%), 
mutants of SHIP1 showed comparable reductions in the phosphorylation of AKT (S473) as 
could be achieved by SHIP1-wt. The amount of SHIP1-wt mRNA and the mRNA amount of 
SHIP1 mutants was comparable (Figure 3C). In consequence, mutation of putative 
phosphorylation sites (S27 and S33) adjacent to the FLVR-motif of SHIP1 have an influence 
on its protein expression. 
 
Analysis of the growth behavior of cells with FLVR motif mutations 
In the next step, the growth behavior of chosen mutants were investigated. First, an Alamar 
Blue cell viability assay was performed. The results in Figure 4A show that, compared to 
control vector expressing cells, cells expressing SHIP1-wt (86.9%±1.4%), K24R 
(74.1%±3.7%), S27A (66%±2.6%), S27D (91%±1.2%), S33A (88.5%±0.5%), S33D 
(62.2%±1.2%) and F28W mutant (81.5%±1.9%) have significantly lower viability. The 
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mutants F28L (97.5%±1.4%) and F28V (95.3%±0.9%) show no significant difference in cell 
viability as compared to control vector expressing cells. 
In addition, the growth behavior of control vector, SHIP1-wt, SHIP1-F28L, SHIP1-F28W and 
SHIP1-K24R expressing H1299 cells was tracked by live cell imaging (IncucyteZoom). For 
this purpose, the respective cells were seeded and confluence of the cells were monitored for 
24 hours. 
The results in Figure 4B show that wild-type SHIP1 (89.5%±4.7%), F28W (79.4%±4.0%) and 
K24R mutant (81.2%±5.2%) had significantly lower cell confluence compared to vector control 
expressing cells. F28L mutant (100.4%±0.94%) showed comparable cell confluence as the 
vector control expressing cells. 
Moreover the half-life of SHIP1 protein was investigated by using cycloheximide to inhibit 
protein synthesis. The half-life of SHIP1-F28L mutant in Jurkat (Figure 5A) and TF-1 (Figure 
5B) cells was drastically reduced compared to half-life of SHIP1 wild type. So half-life analysis 
of SHIP1 in Jurkat cells showed a significantly reduced half-life of SHIP1-F28L protein (0.6 
hours) compared to half-life of SHIP1-wt protein (4.7 hours). In addition, half-life analysis of 
SHIP1 in TF-1 cells showed a significantly reduced half-life of SHIP1-F28L protein (0.89 




Binding of phosphotyrosine-containing motifs (pY) occur by Src homology 2 (SH2) domains 
and phosphotyrosine binding domains (PBD). The SH2 domain usually comprises about 100 
amino acids and is part of over 100 proteins. It was shown that specificity of the SH2 domain 
depends on C-terminal residues of the phosphotyrosine (Songyang et al., 1993). 
In addition to proteins with FLVR motif, some proteins have a related FLIR/YLLR motifs. 
Proteins with FLVR motif are e.g. Src, SHIP1 and ABL1. Proteins with FLIR/YLLR motif 
include Lyn, Grb2, Syk and SH2D1A. These conserved motifs are usually preceded by a 
glycine and a serine or threonine. A glutamic acid and a serine are often located C-terminal of 
the FLVR motif. Thus, the eight amino acid residue motif G (S / T) FLVR (E / D) S defines the 
amino acid sequence essential to the recognition of tyrosine-phosphorylated proteins (Hidaka 
et al., 1991).  
The arginine in the FLVR motif of SH2 domains is the only amino acid of that motif that is 
directly involved in binding of phosphotyrosine. Accordingly, it has previously been shown 
that an arginine-mutant of the FLVR motif can inhibit the binding to phosphotyrosine residues 
(Mayer et al., 1992). Within the scope of this work, the analysis of the Cosmic database 
(https://cancer.sanger.ac.uk/cosmic; Forbes et al., 2011) revealed a number of mutations 
observed in leukemia patients as well as in patients with other tumors, which affect the FLVR 
motif (residues 28-31) or located in close proximity to the FLVR motif of SHIP1. These include 
the mutations F28L (AML), L29F (malignant melanoma), L29L (lung carcinoma), S33T 
(ovarian carcinoma), R38Q (lung carcinoma), A41T (colon carcinoma), A41V (prostate 
carcinoma) and R47W (malignant melanoma). Reduced binding to tyrosine phosphorylated 
proteins has been described for SHIP1-F28L mutation (Brauer et al., 2012). Furthermore, it was 
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shown that the expression of SHIP1-F28L in K562 CML cells, compared to expression of 
SHIP1-wt, can no longer reduce the phosphorylation of AKT-S473 and AKT-T308 (Yang et 
al., 2009).  
The results of this work show that SHIP1 mutations, affecting the FLVR motif of SHIP1 (F28L, 
L29F and R31Q) can lead to a reduced expression of SHIP1 at the protein level. We also showed 
that the expression of SHIP1-wt and SHIP1 mutants of the FLVR motif are comparable at the 
transcriptional level. Closer examination of the SHIP1-F28L mutation revealed that amino 
acids with aromatic residues at position 28 of SHIP1 (F28Y and F28W) preserve the stability 
of the protein, whereas the replacement of an aromatic by a non-aromatic amino acid (F28L, 
F28I, F28V and F28A) severely affects protein stability. From a more detailed structural 
analysis it has become clear that F28 of SHIP1 likely has no direct influence on 
phosphotyrosine-binding because the phenylalanine is too far away from the location of the 
bound phosphotyrosine (the distance between Cζ of F28 and Cζ of R31 is approximately 15 Å).  
However, F28 forms hydrophobic surface contacts in particular with, W5, I83, L97 and P100. 
While both tyrosine and tryptophan at position 28 are able to maintain these interactions, 
replacement of F28 with leucine likely leads to a loss or weakening of these contacts (Figure 
6). It is safe to assume that the (partial) elimination of surface contacts has a significant impact 
on the conformation, flexibility and stability of the SH2 domain that is detrimental to the 
binding of tyrosine-phosphorylated proteins, as observed previously for SHIP1 (Brauer et al., 
2012). 
Defective folding could be identified by ubiquitin ligases. Ubiquitin ligases subsequently 
catalyzes ubiquitination and thus degradation of misfolded proteins (Jackson and Hewitt, 2016). 
The Sattler group has shown previously that SHIP1 is a relatively long-lasting protein with a 
half-life of approximately 17 hours in Ba/F3 cells and half-life is reduced to less than 3 hours 
by the induction of BCR-ABL (Sattler et al., 1999). 
In addition, mutations in the SH2 domain have been shown to destabilize some signaling 
proteins (Fer, ZAP-70, Jak3, ITK and BTK) and cause various diseases (Richardson et al., 2009; 
Matsuda et al., 1999; Candotti et al., 1997; Huck et al., 2009; Lappalainen et al., 2008). These 
mutations are for the most part not involved in phosphotyrosine binding and lead to instability, 
reduced half-life, and in consequence, increased protein degradation (Filippakopoulos et al., 
2009). The X-linked lymphoproliferative syndrome is based on mutations in the SH2D1A gene 
which codes for the SLAM-associated protein (SAP). Two mutations in the SH2D1A gene 
could be identified that affect the G27SYLLRDS motif (S28R and R32Q) (Morra et al., 2001). 
Analysis of these two SH2D1A mutants shows that both mutations lead to a significant 
reduction in half-life compared to wild type (Morra et al., 2001). In addition, it could be shown 
for this R32Q mutation that binding between SH2 domain of SAP and phosphotyrosine of 
CD150 is disturbed (Morra et al., 2001).  
Examination of point mutations of the F168LVRES (ES) motif of the ABL SH2 domain reveals 
that ABL mutations R171K, S173C and S175C disrupt phosphotyrosine binding (Mayer et al., 
1992). Due to the R171K mutation, the binding of ABL to phosphoproteins is impaired (Mayer 
et al., 1992). In contrast, both S173C and S175C mutation can only bind to tyrosine 
phosphorylated proteins at very high concentrations (Mayer et al., 1992). In contrast, ABL 




In addition, analysis of the phosphosite database revealed that a number of putative 
phosphorylation sites (S27, S33, S35, Y40, and Y46) are located in close proximity to the FLVR 
motif of SHIP1 (Hornbeck et al., 2004). In addition, a putative ubiquitinylation site (K24) was 
analyzed. The putative phosphorylation sites are in part highly conserved between the 
individual representatives of the SH2-containing proteins (Supplement Figure S1).  
In particular, the serine at position 33 of SHIP1 can be identified in almost all representatives, 
with the exception of Syk. Interestingly, we found that protein expression of SHIP1 can be 
regulated in particular by the amino acids S27 and S33, which flank the FLVR motif of SHIP1. 
Unexpectedly, pseudophosphorylation of S27 (S27D) resulted in a decreased expression of 
SHIP1, whereas the pseudophosphorylation of S33 (S33D) resulted in an enhanced expression 
of SHIP1. In principle it is known that phosphorylation of proteins can initiate protein 
degradation. Thus, phosphorylation of the so called “phosphodegrone”, a short linear motif, 
generates a surface binding site for ubiquitin ligases (Holt et al., 2012). On the other hand, it 
has been shown that phosphorylation at a specific position can mask a degradation signal (Holt 
et al., 2012). This degradation signal could lead to an increased degradation of SHIP1 by the 
pseudo-dephosphorylation mutant S33A. In addition, it is also conceivable that the added 
phosphate group impairs the binding of phosphotyrosine-containing proteins to the arginine of 
the FLVR motif. The tyrosine kinase Syk has two functionally important SH2 domains. The N-
terminal SH2 domain possesses a YLLR (FLIR) motif and the C-terminal SH2 domain has a 
FLIR sequence. The N-terminal SH2 domain of Syk contains serine 44 (YLLRQS44) in the 
immediate vicinity of the FLIR motif. There is no directly adjacent serine in the C-terminal 
SH2 domain of Syk. However, it has been shown that the SH2 domain forms a loop, which 
takes S202 in close proximity to the FLIR motif of the SH2 domain (Bohnenberger, 2013). 
Analysis of the functional importance of these putative Syk phosphorylation sites revealed that 
following B-cell receptor stimulation, the pseudophosphorylation mutant S202E for the most 
part prevented calcium ion influx and the pseudophosphorylation mutant S44E completely 
prevented calcium ion influx (Bohnenberger, 2013). 
Interestingly, a more detailed investigation of the putative SHIP1 ubiquitinylation site K24 
showed a strong influence on the phosphorylation status of AKT (Figure 3). Accordingly, the 
de-ubiquitinylation mutant K24R led to an increase in the expression of SHIP1 in comparison 
to the expression of SHIP1 wild-type. Consequently, an associated strong reduction in the 
phosphorylation of AKT-S473 was observed. This reduction in the phosphorylation of AKT-
S473 was correspondingly greater than the reduction of the phosphorylation of AKT-S473 that 
could be achieved by the expression of the SHIP1 wild-type. It has previously been shown for 
PTEN that lysine at position 66 also exerts an influence on regulation of its expression status. 
Accordingly, the de-ubiquitination mutant K66R led to an increased expression of PTEN and a 
concomitant reduction in the phosphorylation of AKT S473 and T308 (Gupta and Leslie, 2016). 
Due to the lack of endogenous expression of PTEN in H1299 cells, the expression of SHIP1 
has a direct influence on the phosphorylation of AKT-S473 and moreover on viability and 
growth of the cells. 
 
Conclusion 
In summary, our results demonstrate that SHIP1-FLVR-motif mutations derived from patients 
reveal reduced protein expression and shorter protein half-life. Especially amino acids with 
12 
 
aromatic residues at position 28 of SHIP1 preserve the stability of the protein, whereas the 
replacement of an aromatic to a non-aromatic amino acid severely affects stability of the 
protein. Moreover, we presumably identified FLVR motif flanking phosphorylation sites that 
allow regulation of protein expression. These results further support a functional role of SHIP1 





Abbreviations: PtdIns(3, 4, 5)P3, phosphatidylinositol-(3, 4, 5)-trisphosphate; PtdIns(3, 4)P2, 
phosphatidylinositol-(3, 4)-bisphosphate; SHIP1, src homology 2 domain-containing inositol 
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Figure 1: Investigation of the stability of SHIP1-F28L mutant. (A) Schematic representation 
of the structure of SHIP1. At the N-terminus of SHIP1 the SH2 domain (dark blue) is located. 
The SH2 domain contains the FLVR motif (residues 28-31; light blue). The characteristic 5-
phosphatase domain of SHIP1 is centrally located (yellow). In addition, two nuclear localization 
signals (green), two NPXY motifs (red) and several PxxP motifs (purple) could be identified. 
(B) TF-1 cells were transduced with lentiviral vectors encoding SHIP1-wt, SHIP1-F28L, 
SHIP1-Y643H and control vector. Cells were selected after transduction with Puromycin and 
western blot analysis was performed (C) Three weeks after transduction, in each case RNA of 
transduced cells were isolated. The SHIP1 mRNA amount was determined from the respective 
cDNA by RT-qPCR. The determination of the relative expression of the amount of SHIP1-
mRNA was carried out by normalization to the reference gene GAPDH. Specific 
oligonucleotides were used for transduced SHIP1 (HA-tag). In each case, mean ± standard 
deviation from three measurements of the respective sample is shown. (D) To investigate the 
recovery of SHIP1-F28L at protein level, stable SHIP1-F28L expressing TF-1 cells were treated 
with Src-kinase inhibitor PP2 and proteasomal inhibitor MG132. For this reason, TF-1 cells 
were treated for 24 h with 10 μM PP2, MG132 or DMSO. Lysates of the cells were generated 
by TCA precipitation. In each case 40 μg of protein lysate were separated by SDS-PAGE, 
proteins subsequently transferred to nitrocellulose membrane and detected with specific 
antibodies. 
 
Figure 2: Investigation of the stability of SHIP1 FLVR motif mutants. To study the stability 
of SHIP1 mutants of the FLVR motif and putative phosphorylation sites in the immediate 
vicinity of the FLVR motif, H1299 cells were incubated with lentiviral particles, each vector 
with control vector, SHIP1-wt, SHIP1-F28L, SHIP1-F28I, SHIP1-F28V, SHIP1-F28A, SHIP1-
F28Y, SHIP1-F28W and SHIP1-ΔFLVR sequence, transduced. Cells were selected after 
transduction with puromycin. Subsequently, protein lysates were prepared by TCA 
precipitation and analyzed by western blots with specific antibodies (A). (B) shows 
quantification of relative SHIP1 expression (B1) with corresponding quantification of relative 
p-AKT-S473 expression (B2) of H1299 cells. Three weeks after transduction, RNA of 
transduced cells was isolated. The SHIP1 mRNA amount was determined from the respective 
cDNA by RT-qPCR. The determination of the relative expression of the amount of SHIP1-
mRNA was carried out by normalization to the reference gene GAPDH. Specific 
oligonucleotides were used for transduced SHIP1 (HA-tag) (C). In each case, mean ± standard 
deviation from three measurements of the respective sample is shown. 
 
Figure 3: Investigation of the influence of putative phosphorylation sites in the immediate 
vicinity of the FLVR motif of SHIP1 on protein stability. To study the stability of SHIP1 
mutants of the FLVR motif and putative phosphorylation sites in the immediate vicinity of the 
FLVR motif, H1299 cells were incubated with lentiviral particles, each vector with control 
vector, SHIP1-wt, SHIP1-K24R, SHIP1-S27A, SHIP1-S27D, SHIP1-F28L, SHIP1-L29F, 
SHIP1-R31Q, SHIP1-S33A, SHIP1-S33D, SHIP1-S35A, SHIP1-S35D, SHIP1-Y40A and 
SHIP1-Y46A sequences, transduced. Cells were selected after transduction with puromycin. 
Subsequently, protein lysates were prepared by TCA precipitation and analyzed by western 
blots with specific antibodies (A). (B) shows quantification of relative SHIP1 expression (B1) 
with corresponding quantification of relative p-AKT-S473 expression (B2) of H1299 cells. 
Three weeks after transduction, RNA of transduced cells was isolated. The SHIP1 mRNA 
amount was determined from the respective cDNA by RT-qPCR. The determination of the 
relative expression of the amount of SHIP1-mRNA was carried out by normalization to the 
reference gene GAPDH. Specific oligonucleotides were used for transduced SHIP1 (HA-tag) 





Figure 4: Analysis of the influence of SHIP1 FLVR motif mutants on growth behavior of 
H1299 cells. (A) To investigate the influence of SHIP1-FLVR motif mutants on growth 
behavior of H1299 cells, control vector, SHIP1-wt, SHIP1-F28L, SHIP1-F28W and K24R-
expressing H1299 cells were seeded in triplicates at a cell density of 3 × 104 cells/well in 200 
µl medium in a 96-well dish. 48 hours after seeding, addition of resazurin was used to measure 
the discoloration of the medium as an indicator of cell viability. (B) Using a live cell imaging 
analysis system, growth behavior of the cells was monitored over 24 hours. Stable SHIP1-wt, 
SHIP1-K24R, SHIP1-S27A, SHIP1-S27D, SHIP1-F28L, SHIP1-S33A, SHIP1-S33D, SHIP1-
F28V and SHIP1-F28W expressing H1299 cells together with vector control expressing cells 
were each seeded in triplicates at a cell density of 3 x 104 cells/well in 100 µl medium in a 96-
well dish. Statistical significance refers to control vector expressing cells (* p≤0.05; ** p≤0.01; 
*** p≤0.001). 
 
Figure 5: Investigation of half-life of SHIP1-wt and SHIP1-F28L mutant in Jurkat and 
TF-1 cells. Half-life of SHIP1 protein was analyzed by using cycloheximide to inhibit protein 
synthesis. SHIP1-wt and SHIP1-F28L expressing Jurkat (A) and TF-1 (B) cells were seeded 
and incubated with cycloheximide or DMSO. Protein lysates were prepared as indicated at 
different time points. Protein lysate were separated by SDS-PAGE, proteins subsequently 
transferred to nitrocellulose membrane and detected with specific antibodies. The experiment 
was performed in triplicate. Images of representative Western blots are shown. Subsequently, 
expression intensity was quantified and half-life was calculated (see diagrams). Mean ± 
standard deviation are shown. Intensity of the Western blot bands observed at time point 0h 
(untreated) was set to 100% 
 
Figure 6: Visualization of the (A) SHIP1-wt and (B) SHIP1-F28L mutant based on a 
SHIP1-wt NMR structure (PDB2YSX). (A) Aromatic amino acids at position 28 (F, W and 
Y) form hydrophobic surface contacts in particular with, W5, I83, L97 and P100. (B) The 
smaller-sized leucine at position 28 likely leads to a (partial) loss of these surface contacts, with 
significant impact on the conformation, flexibility and stability of the SH2 domain. 
 
 
Figure S1: Representation of the conserved FLVR motif in SH2 domain-containing 
proteins. The FLVR motif (residue 28-31, according to SHIP1 sequence) or the related FLIR 
or YLLR motif is flanked by putative phosphorylation sites. Serine or threonine residues are 
often located N-terminal of the FLVR motif (residue 27). Glutamic acid / aspartic acid (residue 
32) followed by a serine (residue 33) is often located C-terminal of the FLVR motif. At amino 
acid position 35, a serine or threonine residue is also usually found. 
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